04-12-2009 (Ad hoc press release)

Eckert & Ziegler: capital increase successfully concluded / clear oversubscription

03-12-2009 (Ad hoc press release)

Eckert & Ziegler: Re-Enter the U.S Market with Therapeutic Products


Eckert & Ziegler winner of "Selected Landmarks in the Land of Ideas 2010"

13-11-2009 (Ad hoc press release)

Eckert & Ziegler: Strike price for capital increase at 15.95 EUR per share and other details of the capital increase also fixed

10-11-2009 (Ad hoc press release)

Eckert & Ziegler resolves capital increase


Eckert & Ziegler: Record sales and a strong capital flow


Eckert & Ziegler commissioned to produce an innovative cancer medication


Eckert & Ziegler awards grants to young researchers in nuclear medicine


Eckert & Ziegler: Choosing the IBt Bebig Temporary Brachytherapy solution MultiSource® HDR Co-60 afterloader


Eckert & Ziegler: Shares from the capital increase of February 2009 authorised for trading (Prime Standard)


Eckert & Ziegler continues on record course. Strongest half year in company history.

20-07-2009 (Ad hoc press release)

Eckert & Ziegler achieves best six-month result and raises profit forecast


Eckert & Ziegler: 1,000th patient Treated with I-125 implants at Christie Hospital, Manchester - England


Hearings on IBt Take-over Bid Case Moved up to November


Eckert & Ziegler's associated company IBt Bebig signs contracts about a joint venture in the Russian Federation


Eckert & Ziegler: Stock Buy Back Programme Approved

29-05-2009 (Ad hoc press release)

Eckert & Ziegler appeals against CBFA decision


Eckert & Ziegler: New Heights in Revenues and Profits in Q 1 2009

28-04-2009 (Ad hoc press release)

Belgian Securities Regulator Requires Take-over Bid but Suspends Action


IBt and Russian state fund set up joint venture to manufacture prostate cancer implants in Russia